Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy

161Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

Abstract

Background - Intravitreal neovascular diseases, as in ischemic retinopathies, are a major cause of blindness. Because inflammatory mechanisms influence vitreal neovascularization and cyclooxygenase (COX)-2 promotes tumor angio-genesis, we investigated the role of COX-2 in ischemic proliferative retinopathy. Methods and Results - We describe here that COX-2 is induced in retinal astrocytes in human diabetic retinopathy, in the murine and rat model of ischemic proliferative retinopathy in vivo, and in hypoxic astrocytes in vitro. Specific COX-2 but not COX-1 inhibitors prevented intravitreal neovascularization, whereas prostaglandin E2, mainly via its prostaglandin E receptor 3 (EP3), exacerbated neovascularization. COX-2 inhibition induced an upregulation of thrombospondin-1 and its CD36 receptor, consistent with the observed antiangiogenic effects of COX-2 inhibition; EP3 stimulation reversed effects of COX-2 inhibitors on thrombospondin-1 and CD36. Conclusion - These findings point to an important role for COX-2 in ischemic proliferative retinopathy, as in diabetes.

Cite

CITATION STYLE

APA

Sennlaub, F., Valamanesh, F., Vazquez-Tello, A., El-Asrar, A. M., Checchin, D., Brault, S., … Chemtob, S. (2003). Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation, 108(2), 198–204. https://doi.org/10.1161/01.CIR.0000080735.93327.00

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free